Vinorelbine has a number of side-effects that can limit its use:
Chemotherapy-induced peripheral neuropathy (a progressive, enduring and often irreversible tingling numbness, intense pain, and hypersensitivity to cold, beginning in the hands and feet and sometimes involving the arms and legs[10]), lowered resistance to infection, bruising or bleeding,
anaemia,
constipation, vomitings,
diarrhea,
nausea, tiredness and a general feeling of weakness (
asthenia), inflammation of the vein into which it was injected (
phlebitis). Seldom severe
hyponatremia is seen.
Less common effects are hair loss and allergic reaction.
Pharmacology
The antitumor activity is due to inhibition of mitosis through interaction with tubulin.[11]
History
Vinorelbine was invented by the pharmacist
Pierre Potier and his team from the
CNRS in
France in the 1980s and was licensed to the oncology department of the
Pierre Fabre Group. The drug was approved in France in 1989 under the brand name Navelbine for the treatment of non-small cell
lung cancer. It gained approval to treat
metastatic breast cancer in 1991. Vinorelbine received approval by the
United StatesFood and Drug Administration (FDA) in December 1994 sponsored by Burroughs Wellcome Company. Pierre Fabre Group now markets Navelbine in the U.S., where the drug went generic in February 2003.
In most European countries, vinorelbine is approved to treat non-small cell lung cancer and breast cancer. In the United States it is approved only for non-small cell lung cancer.
An oral formulation has been marketed and registered in most European countries. It has similar efficacy as the intravenous formulation, but it avoids venous toxicities of an infusion and is easier to take.[medical citation needed] The oral form is not approved in the United States, or Australia.[medical citation needed]
References
^
abcBritish national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 594.
ISBN9780857111562.
^Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, et al. (November 2001). "Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors". Annals of Oncology. 12 (11): 1643–1649.
doi:
10.1023/A:1013180903805.
PMID11822766.
^
abcdefgh"Vinorelbine Tartrate". The American Society of Health-System Pharmacists.
Archived from the original on 21 December 2016. Retrieved 8 December 2016.
^World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization.
hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
^World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization.
hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.